Related Experiment Video

Updated: Jun 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Antagonists of IAP proteins as cancer therapeutics

Jasmin N Dynek1, Domagoj Vucic

  • 1Department of Protein Engineering, Genentech, Inc., South San Francisco, CA 94080, USA.

Cancer Letters
|August 6, 2010
PubMed

Insights

Inhibitor of apoptosis (IAP) proteins promote cancer cell survival and treatment resistance. Targeting these proteins with antagonists offers a promising strategy for cancer therapy development.

Area of Science:

  • Cellular Biology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Inhibitor of apoptosis (IAP) proteins are crucial regulators of programmed cell death (apoptosis).
  • These proteins prevent apoptosis triggered by various stimuli, including chemotherapy and radiation.
  • Dysregulation of IAP proteins contributes to cancer progression and resistance to cancer treatments.

Purpose of the Study:

  • To review the multifaceted roles of IAP proteins in cancer development.
  • To explore the therapeutic potential of IAP antagonists in cancer treatment.

Main Methods:

  • Literature review of studies on IAP proteins in cancer.
  • Analysis of IAP gene alterations in human malignancies.
  • Discussion of IAP antagonist development and preclinical/clinical data.

Main Results:

  • IAP proteins are frequently overexpressed, amplified, or mutated in various cancers.
  • Evasion of apoptosis mediated by IAPs confers resistance to standard cancer therapies.
  • IAP antagonists have shown promise in preclinical models, often in combination therapies.

Conclusions:

  • IAP proteins are significant drivers of cancer cell survival and therapeutic resistance.
  • Targeting IAP proteins represents a viable strategy for developing novel cancer treatments.
  • Further research into IAP antagonists may lead to improved patient outcomes in oncology.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...